Vanderbilt is a globally renowned research university. They have gained steady ground in research and the fight against cancer and brain disorders. They have also developed new therapies for leukemia and colorectal cancer and are making progress on new treatments for breast and liver cancer.
Vanderbilt University Medical Center was awarded a $31.8M NIH grant for The Precision Medicine Initiative with a project end date of December 2022. The all-encompassing objective of the Precision Medicine Initiative’s (PMI) is to transform our understanding of the factors that contribute to health and disease, and eventually, to use this data so we can prevent and treat disease. This funding for Vanderbilt and PMI has been extended thru 2019.
In addition, colorectal cancer (CRC) remains the second most common cause of cancer death in the United States. The National Cancer Institute recently awarded Vanderbilt almost $11M in funding to study the prevention of colorectal cancer (CRC) with single cell analysis.
- Total R & D Expenditures:$712,036,000
- Ranked 31st in total R & D expenditures
- 2017 Life Science R & D Expenditures:$542,857,000
- 2018 NIH Funding: $102,275,777
Biotechnology Calendar will be hosting the 1st Annual BioResearch Product Faire™ event on June 7th, 2019. Meet face to face with active researchers in the Vanderbilt marketplace and educate these scientists on your products and services while you discover their needs, help them find solutions, and build long lasting relationships.
Vanderbilt BioResearch Product Faire™ Thursday, October 3rd, 2019
With ample funding, Vanderbilt researchers are eager to purchase state-of-the-art laboratory products and services. Call today to reserve your space in this prestigious marketplace and the event coming in June.